How have CRTX shares performed in 2024?

Cortexyme's stock was trading at $1.05 at the start of the year. Since then, CRTX stock has increased by 1.0% and is now trading at $1.06. View the best growth stocks for 2024 here .

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA) , Gran Tierra Energy (GTE) , Bionano Genomics (BNGO) , DHT (DHT) , EnLink Midstream (ENLC) , Golar LNG Partners (GMLP) , Matinas BioPharma (MTNB) , Organigram (OGI) , Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS) .

When did Cortexyme IPO?

Cortexyme (CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free CRTX Stock Alerts

$1.06

+0.06 (+6.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.98
▼
$1.07
50-Day Range: $0.99
▼
$1.95
52-Week Range: $1.78
▼
$40.66

Volume: 80,582 shs
Average Volume: 620,672 shs
Market Capitalization: $31.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Insider Trades Social Media

Get Cortexyme alerts:

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About Cortexyme Stock (NASDAQ:CRTX)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRTX Stock News Headlines

August 1, 2022 | marketscreener.com

Cortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.com

July 27, 2022 | marketscreener.com

Cortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.com

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

July 27, 2022 | businesswire.com

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business Wire

July 27, 2022 | businesswire.com

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business Wire

July 27, 2022 | marketscreener.com

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.com

July 27, 2022 | finance.yahoo.com

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo Finance

July 27, 2022 | finance.yahoo.com

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

July 27, 2022 | finance.yahoo.com

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

July 22, 2022 | streetinsider.com

Cortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.com

June 26, 2022 | gurufocus.com

Bragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.com

June 21, 2022 | benzinga.com

Cortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - Benzinga

June 21, 2022 | nasdaq.com

Cortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - Nasdaq

June 21, 2022 | finance.yahoo.com

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

June 13, 2022 | businesswire.com

Cortexyme Appoints June Bray to its Board of Directors - Business Wire

June 13, 2022 | finance.yahoo.com

Cortexyme Appoints June Bray to its Board of Directors - Yahoo Finance

June 13, 2022 | finance.yahoo.com

Cortexyme Appoints June Bray to its Board of Directors

June 11, 2022 | marketscreener.com

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.com

June 10, 2022 | marketscreener.com

Cortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com

May 22, 2022 | businesswire.com

Cortexyme Successfully Completes Acquisition of Novosteo - Business Wire

May 20, 2022 | nasdaq.com

This Is the Worst Type of Credit Card for Most Consumers - Nasdaq

May 20, 2022 | finance.yahoo.com

PPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo Finance

May 20, 2022 | marketscreener.com

Cortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.com

May 20, 2022 | finance.yahoo.com

Cortexyme Successfully Completes Acquisition of Novosteo - Yahoo Finance

May 20, 2022 | finance.yahoo.com

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

May 13, 2022 | nasdaq.com

Pre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - Nasdaq

See More Headlines

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: Health Care Technology
Current Symbol: NASDAQ:CRTX
CUSIP: 21924P10
CIK: 1145404
Web: www.cortexyme.com
Phone: (650) 910-5717
Fax: N/A
Employees: 55
Year Founded: 2012

Profitability

EPS (Most Recent Fiscal Year): ($2.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,940,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -70.96%
Return on Assets: -63.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.92
Quick Ratio: 9.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.97 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 30,151,000
Free Float: 21,739,000
Market Cap: $31.96 million
Optionable: Not Optionable
Beta: 1.40

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Leslie J. Holsinger Ph.D. (Age 57)
Exec. VP of R&D
Comp: $603.85k
Dr. Dirk Thye M.D. (Age 52)
CEO & Director
Mr. Ted Monohon (Age 56)
VP of Fin., Principal Financial Officer & Chief Accounting Officer
Mr. Brendan Hannah M.B.A.
Chief Bus. Officer
Dr. Karen L. Smith L.L.M (Age 54)
L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer

Key Competitors

View All Competitors

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed in 2024?: Cortexyme's stock was trading at $1.05 at the start of the year. Since then, CRTX stock has increased by 1.0% and is now trading at $1.06.
View the best growth stocks for 2024 here.
How were Cortexyme's earnings last quarter?: Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.05.
What other stocks do shareholders of Cortexyme own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS).

When did Cortexyme IPO?: Cortexyme (CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
How do I buy shares of Cortexyme?: Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cortexyme (CRTX) Stock Price, News & Analysis

About Cortexyme Stock (NASDAQ:CRTX)

CRTX Stock Price History

CRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

CRTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info